Premium
Usefulness of the CLLflow score
Author(s) -
Sorigue Marc,
FranchSarto Mireia,
Sarrate Edurne,
Junca Jordi
Publication year - 2018
Publication title -
cytometry part b: clinical cytometry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.646
H-Index - 61
eISSN - 1552-4957
pISSN - 1552-4949
DOI - 10.1002/cyto.b.21623
Subject(s) - immunophenotyping , cd5 , medicine , chronic lymphocytic leukemia , gastroenterology , lymphoproliferative disorders , bone marrow , standard score , leukemia , lymphoma , flow cytometry , immunology , machine learning , computer science
Background The CLLflow score was recently suggested as an improvement over the Moreau score (MS) for the diagnosis and classification of B‐cell lymphoproliferative disorders (B‐LPD). Methods We determined the CLLflow score in peripheral blood or bone marrow of a series of cases with an inconclusive immunophenotype, including samples with a MS of 3 ( n = 52) and CD5‐positive with a score of 2 ( n = 38). As controls, B‐LPD with a MS of 0–1 ( n = 95), CD5‐negative score 2 ( n = 24), and score 4–5 (i.e., chronic lymphocytic leukemia [CLL], n = 166) were included. Results The CLLflow score was positive (suggestive of CLL) in all CLL cases and negative in all MS <2, regardless of CD200‐positivity, which occurred in 31% (29/95) of cases. The CLLflow score was positive in 71%, 29%, and 8% of samples with a MS 3, CD5‐positive score 2, and CD5‐negative score 2, respectively. Discussion Our results suggest that the CLLflow is useful in the differential diagnosis of cases with inconclusive immunophenotype. © 2018 International Clinical Cytometry Society